Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-743921 · 1 trial · 2 indications
Maximum Tolerated Dose (MTD) was determined by testing increasing doses in cohorts with at least 3 patients each. MTD reflects the highest dose of drug that did not cause dose limiting toxicity (DLT).
| Arm | Type | Description |
|---|---|---|
| Phase 1 Dose Escalation | EXPERIMENTAL | Phase 1 dose escalation without and with GCSF support |
| Phase 2 Fixed Dose | EXPERIMENTAL | Phase 2 fixed dose based on Phase I findings stratified by NHL type |
| Name | Type | Description |
|---|---|---|
| SB-743921 | DRUG | Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops. |
Inclusion Criteria: Phase 1: Patients with evaluable or measurable (by MRI or CT) Hodgkin's Disease or Non-Hodgkin's Lymphoma. Phase 2: Patients with Measurable Non-Hodgkin's Lymphomas (Indolent or Aggressive) only. - Patients with Indolent NHL must be relapsed or refractory to at least one prior li...
SB-743921 is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma. It is in Phase 1 clinical development and is not yet approved by the FDA. The drug is being evaluated in patients with Non-Hodgkin's Lymphoma and Hodgkin's Disease.
SB-743921 is being developed by Cytokinetics, Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CYTK. The company is conducting clinical research on this investigational oncology drug.
SB-743921 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research for Non-Hodgkin's Lymphoma.
SB-743921 has one completed Phase 1 clinical trial, identified as NCT00343564. This study evaluated SB-743921 in patients with Non-Hodgkin's Lymphoma and Hodgkin's Disease, enrolling 68 participants across the United States and Russia.
SB-743921 is the primary name used for this investigational drug in clinical trials. No alternative names have been reported for this compound in the available clinical trial information.